Pentamidine

BreastfeedingPediatric
  • TRADE NAMES: NebuPent (Astellas); Pentacarinat (Sanofi-Aventis); Pentam 300 (Astellas)
  • INDICATIONS: Pneumocystis jiroveci infection, trypanosomiasis, leishmaniasis
  • CLASS: Antiprotozoal
  • HALF-LIFE: 9.1–13.2 hours (intramuscular); 6.5 hours (intravenous)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Adefovir, Aminoglycosides, Amiodarone, Amisulpride, Amitriptyline, Amphotericin B, Cisplatin, Droperidol, Erythromycin, Foscarnet, Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Ivabradine, Levomepromazine, Moxifloxacin, Phenothiazines, Saquinavir, Sparfloxacin, Sulpiride, Tricyclic antidepressants, Trifluoperazine, Vancomycin

PREGNANCY CATEGORY: C

The rate of adverse side effects is increased in patients with AIDS.

Our database has 39 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
LOCAL
NEUROMUSCULAR/SKELETAL
RESPIRATORY
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top